This article explores the risks and rewards associated with public-private partnership ("P3")
initiatives and provides a framework through which these initiatives can achieve success by …

So many discussions go astray because the same words are used in different senses by
adherents of different points of view that it seems imperative to start practically every discussion …

A decisive step in the biosynthesis of many proteins is their partial or complete translocation
across the eukaryotic endoplasmic reticulum membrane or the prokaryotic plasma …

PURPOSE Although the majority of patients with relapsed or refractory large B-cell lymphoma
respond to axicabtagene ciloleucel (axi-cel), only a minority of patients have durable …

PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed
chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell …

Introduction: Brexucabtagene autoleucel (brexu-cel) was approved by US FDA for relapsed/refractory
(R/R) mantle cell lymphoma (MCL) on July 24, 2020 based on results from the …

Discovery in construction litigation | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ
[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本をさがす 日本の …

Introduction: The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy,
axicabtagene ciloleucel (Axi-cel) improved long-term survival of patients with relapsed/refractory …

Publishing in the field of construction litigation has become prolific business. The specialty
is growing explosively, and publication, like giving seminars and appearing on panels, is …

Background: The ZUMA-2 trial and real-world studies showed high efficacy of brexucabtagene
autoleucel (brexu-cel) in relapsed/refractory mantle cell lymphoma (MCL). We previously …